Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.

@article{OBrien2008ValganciclovirPC,
  title={Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.},
  author={Susan M O'Brien and Farhad Ravandi and Todd Riehl and William G Wierda and Xuelin Huang and Jeffrey P Tarrand and B O'neal and Hagop A Kantarjian and Michael Keating},
  journal={Blood},
  year={2008},
  volume={111 4},
  pages={1816-9}
}
Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells. Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent. Approximately 20% to 25% of patients will experience cytomegalovirus (CMV) reactivation. We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily. The study design planned to… CONTINUE READING
41 Extracted Citations
13 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 41 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 13 references

Valganciclovir

  • M Curran, S Noble
  • Drugs
  • 2004

Similar Papers

Loading similar papers…